Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

In a report released on May 8, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $86.00. The company’s sha...

Xenon (XENE) Gets a Buy from Stifel Nicolaus

Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Xenon on May 8 and set a price target of $69.00. The company’s shares closed last F...

Wells Fargo Remains a Buy on Xenon (XENE)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Xenon today and set a price target of $80.00. Kasimov covers the Healthcare sector, fo...

Evercore ISI Sticks to Their Buy Rating for Xenon (XENE)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Xenon today and set a price target of $74.00. Tsao covers the Healthcare sector, fo...

H.C. Wainwright Remains a Buy on Xenon (XENE)

Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported first-quarter 2026 results on May 7, highlighting positive Phase 3 X-TOLE...

Xenon Highlights Positive Phase 3 Azetukalner Seizure Data

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $89.00. Matteis covers the H...

Current Quarter	$-1.16	Next Quarter	$-1.16
Current Year	$-4.88	Next Year	$-4.98
QoQ Growth	+0.0%	YoY Growth	-2.0%
3Y EPS CAGR	-28.4%	Target Price	$80.44
Consensus	Buy	Upside	+49.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$53.98	-0.35%	1.83M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$53.98	-0.4%	1.83M
3
4
5
6

XENE

XENE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel